Abstract
The five dose comparative CNS Cancer Cell Line cytotoxicity profiles of N9-[4'-Chloro-2'-butynyl-1'-yl]-2,6- dichloropurine 1, Bis- 6,9-[4'-chloro-2'-butynyl-1'-yl]-thioguanine 2, Bis- 6,9-[4'-chloro-2'-butynyl-1'-yl]-mercaptopurine 3, Bis-6,9-[[o-(chloromethyl)phenyl]methyl]-thioguanine 4, Bis-6,9-[[o-(chloromethyl)phenyl]methyl]-mercaptopurine 5, 6-[4'-chloro-2'-butynyl-1'-yl]-thioguanine 6, and N9-[4'-Chloro-2'-butynyl-1'-yl]-6-(4-methoxyphenyl)purine 7 are presented in this communication. These compounds were evaluated for cytotoxic activity against NCI-60 DTP human tumor cell line five dose screen. All the unsaturated highly lipophilic substituents as expected contributed for the excellent CNS cancer cell line cytotoxicity, GI50 values 4-7 μM. Further, the thioguanine, mercaptopurine, and 6-phenylpurine are identified as the potential candidates for the CNS active cancer drug development and to cross the blood brain barrier.
Keywords: CNS, prostates, Cancer, leukemia, 60-cell lines, chemotherapeutic agents, breast cancer, metabolic pathways, proliferation, taxanes
Letters in Drug Design & Discovery
Title:CNS Cancer Cell Line Cytotoxicity Profiles of Some 2, 6, 9-Substituted Purines: A Comparative Five-Dose Testing Study
Volume: 9 Issue: 5
Author(s): Tien N. Banh, Nageswara R. Kode, Shashikan Phadtare
Affiliation:
Keywords: CNS, prostates, Cancer, leukemia, 60-cell lines, chemotherapeutic agents, breast cancer, metabolic pathways, proliferation, taxanes
Abstract: The five dose comparative CNS Cancer Cell Line cytotoxicity profiles of N9-[4'-Chloro-2'-butynyl-1'-yl]-2,6- dichloropurine 1, Bis- 6,9-[4'-chloro-2'-butynyl-1'-yl]-thioguanine 2, Bis- 6,9-[4'-chloro-2'-butynyl-1'-yl]-mercaptopurine 3, Bis-6,9-[[o-(chloromethyl)phenyl]methyl]-thioguanine 4, Bis-6,9-[[o-(chloromethyl)phenyl]methyl]-mercaptopurine 5, 6-[4'-chloro-2'-butynyl-1'-yl]-thioguanine 6, and N9-[4'-Chloro-2'-butynyl-1'-yl]-6-(4-methoxyphenyl)purine 7 are presented in this communication. These compounds were evaluated for cytotoxic activity against NCI-60 DTP human tumor cell line five dose screen. All the unsaturated highly lipophilic substituents as expected contributed for the excellent CNS cancer cell line cytotoxicity, GI50 values 4-7 μM. Further, the thioguanine, mercaptopurine, and 6-phenylpurine are identified as the potential candidates for the CNS active cancer drug development and to cross the blood brain barrier.
Export Options
About this article
Cite this article as:
Tien N. Banh, Nageswara R. Kode, Shashikan Phadtare , CNS Cancer Cell Line Cytotoxicity Profiles of Some 2, 6, 9-Substituted Purines: A Comparative Five-Dose Testing Study, Letters in Drug Design & Discovery 2012; 9 (5) . https://dx.doi.org/10.2174/157018012800389241
DOI https://dx.doi.org/10.2174/157018012800389241 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Statins: A Conceivable Remedial Role for the Regulation of Cancer Progression
Current Cancer Therapy Reviews Breast Cancer Image Classification: A Review
Current Medical Imaging Adenovirus-based Immunotherapy for Prostate Cancer
Current Cancer Therapy Reviews α7 Nicotinic Acetylcholine Receptor Mediated Neuroprotection in Parkinson’s Disease
Current Drug Targets Targeting Ion Channels in Cancer: A Novel Frontier in Antineoplastic Therapy
Current Medicinal Chemistry Protective Effects of Melatonin and Mitochondria-targeted Antioxidants Against Oxidative Stress: A Review
Current Medicinal Chemistry The Role and Therapeutic Potential of Ser/Thr Phosphatase PP2A in Apoptotic Signalling Networks in Human Cancer Cells
Current Molecular Medicine CuAAC Click Chemistry Accelerates the Discovery of Novel Chemical Scaffolds as Promising Protein Tyrosine Phosphatases Inhibitors
Current Medicinal Chemistry Peptide-Drug Conjugate: A Novel Drug Design Approach
Current Medicinal Chemistry Patent Selections:
Recent Patents on Inflammation & Allergy Drug Discovery Tubulin Inhibitors: A Patent Survey
Recent Patents on Anti-Cancer Drug Discovery Colloidal Supramolecular Aggregates for Therapeutic Application in Neuromedicine
Current Medicinal Chemistry Design, Synthesis and Anticancer Evaluation of Carbazole Fused Aminopyrimidine Derivatives
Letters in Organic Chemistry Hybrid SPECT/CT Imaging in Neurology
Current Radiopharmaceuticals Sentinel Node Biopsy in Early Breast Cancer
Medicinal Chemistry Back to the Bench? MEK and ERK Inhibitors for the Treatment of KRAS Mutant Lung Adenocarcinoma
Current Medicinal Chemistry Antibody Engineering for Targeted Therapy of Cancer Recombinant Fv-Immunotoxins
Current Pharmaceutical Biotechnology Targeting the G2/M Transition for Antitumor Therapy
Letters in Drug Design & Discovery Comparison of Paraben Stability in Human and Rat Skin
Drug Metabolism Letters What are the Cancer Risks in BRCA Carriers Apart from Those Regarding the Breast and the Ovary?
Current Women`s Health Reviews